HCW Biologics (HCWB) announced that Peter Rhode, PhD, Chief Scientific Officer and Vice President of Clinical Operations of HCW Biologics, participated in a Virtual Investor “What This Means” segment. Dr. Rhode’s presentation features the Company’s lead product candidate, known as HCW11-040, which is the Company’s immunotherapeutic for internal clinical development as a second-generation immune checkpoint inhibitor. HCW11-040 is a multi-functional fusion protein constructed using the Company’s novel drug discovery and development platform, called the TRBC platform.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCWB:
- HCW Biologics Granted Nasdaq Compliance Extension
- HCW Biologics congratulates Wugen on equity financing
- HCW Biologics’ Innovative Lead Candidate HCW11-040 Boosts Cancer Therapy Potential
- HCW Biologics announces results from second-gen T-cell engager programs
- HCW Biologics Extends License Fee Payment Deadline